Document is current

Article History

Received: 16 May 2023

Accepted: 22 September 2023

First Online: 18 October 2023

Declarations

:

: RWM — Consulting: Genmab, Adaptive Biotechnologies, Bristol Myers Squibb, Abbvie, Intellia, Epizyme. Research funding: Bristol Myers Squibb, Merck, Genentech/Roche, Genmab.RAR — none.ASF — none.IEA — Consulting: BeiGene.JRB — consultant for Abbvie, Acerta/Astra-Zeneca, BeiGene, Eli Lilly, Genentech/Roche, Grifols Worldwide Operations, Hutchmed, iOnctura, Janssen, MEI Pharma, Numab Therapeutics, Pfizer, Pharmacyclics; received research funding from BeiGene, Gilead, iOnctura, Loxo/Lilly, MEI Pharma, SecuraBio, TG Therapeutics.JLC — Consultancy: Karyopharm, Kite, Morphosys, Incyte, ADC Therapeutics, Research Funding: Genentech/Roche, Merck, Abbvie, Bayer.MSD — consulting fees from AbbVie, Adaptive Biosciences, Aptitude Health, Ascentage Pharma, AstraZeneca, BeiGene, Bio Ascend, BMS, Celgene, Curio Science, Eli Lilly, Genentech, Janssen, Merck, Ono Pharmaceuticals, Research to Practice, Secura Bio, TG Therapeutics, Takeda, and research support from AbbVie, AstraZeneca, Ascentage Pharma, Genentech, MEI Pharma, Novartis, Surface Oncology, TG Therapeutics.DCF — none.EDJ — Consulting: Syros, Takeda. Research funding: Acerta, Janssen, Novartis, Pharmacyclics.AIK — none.ASL — Consulting: Research to Practice. Advisory ad boards: Kite and Seagen.SN — none.OOO — none.EMP — none.II — consultant for Celgene/Jazz, Kite, Epizyme, Beam Therapeutics, and ADC Therapeutics.JK — Consulting: Merck, ADC Therapeutics, Gilead, Daiichi Sankyo, BeiGene, SecuraBio. Research support: Merck, SecuraBio. Speakers’ Bureau: Kite/Gilead.JBC — Advisory Board: Abbvie, Janssen, Astra Zeneca, BeiGene, Kite, ADCT, Hutchmed, Loxo/Lilly. Research Funding: Genentech, Takeda, Lilly/Loxo, Celgene/BMS, Astra Zeneca, HutchMed.NM-S — institutional clinical trial funding from AstraZeneca, Bristol Myers-Squibb, Celgene, C4 Therapeutics, Corvus Pharmaceuticals, Daiichi Sankyo, Genentech/Roche, Innate Pharmaceuticals, Secura Bio/Verastem, Yingli Pharmaceuticals and Dizal Pharmaceuticals. She has received compensation for service as a consultant for AstraZeneca, Secura Bio/Verastem, Daiichi Sankyo, C4 Therapeutics, Genentech, Karyopharm Therapeutics, Kyowa Hakko Kirin, and Ono pharmaceuticals.NLB — Consultancy/Advisory Boards: SeaGen, Roche/Genentech, Kite/Gilead, Foresight Diagnostics. Research funding (Institution): ADC Therapeutics, BMS/Celgene, Kite/Gilead, Merck, Millennium, Pharmacyclics, Roche/Genentech, SeaGen.MM — Advisory board: Novartis, Seattle Genetics, CTI, Janssen, EUSA; Speaker’s bureau: Seattle Genetics, Monjuvi.TMK — none.JOW — none.SJR — Research fundings: Bristol Myers Squibb and KITE/Gilead. Member of the SAB for Immunitas Therapeutics.PA — Consultancy: Merck, BMS, Pfizer, Affimed, Adaptive, Infinity, ADC Therapeutics, Celgene, Morphosys, Daiichi Sankyo, Miltenyi, Tessa, GenMab, C4, Enterome, Regeneron, Epizyme, Astra Zeneca, Genentech, Xencor. Research funding: Kite. Research funding (institutional): Merck, BMS, Affimed, Adaptive, Tensha, Otsuka, Sigma Tau, Genentech/Roche, IGM. Honoraria: Merck, BMS.CAJ — Consulting: Kite/Gilead, Novartis, BMS/Celgene, bluebird bio, Epizyme, Ipsen, Instil Bio, ImmPACT Bio, Caribou Bio, Morphosys, Miltenyi, Abintus Bio. Research funding: Kite/Gilead and Pfizer.